A well-known diabetes drug could be used to help people who suffer from Parkinsons disease. Researchers have concluded a year-long study and discovered that people who took exenatide weekly had better motor functions compared to a control group. The study, published in The Lancet, followed 60 people with Parkinsons disease. Thirty-one of them had an injection of exenatide once a week for 48 weeks, while the rest received a placebo injection. People on exenatide performed better in motor tests at the end of the trail compared to the control group. They were then tested again 12 weeks later, with the people on exenatide still performing better. This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms, senior author Professor Tom Foltynie, from University College London, said in a statement. With existing treatments, we can relieve most of the symptoms for some years, but the disease continues to worsen. The patients in the drug group did not report a significant improvement in their day-to-day life compared to the current treatment. It also needs to be clear that the research didnt conclusively prove that exenatide was actually affecting the disease, it might simply be reducing its symptoms. While we are optimistic about the results of our trial, there is more investigation to be done, and it will be a number of years before a new treatment could be approved and ready for use. We also hope to learn why exenatide appears to work better for some patients than for others, said the studys first author, Dr Dilan Athauda from UCL’s Institute of Neurology. Exenatide has been used since 2005 to treat Type 2 diabetes. It activates receptors in the pancreas that stimulates insulin release. The same receptors are found in the brain where they improve the function of dopamine connections. Symptoms for Parkinsons only become apparent after 70 percent of the brains dopamine-producing cells have been affected by the condition, so that’s where the drug’s effect comes into play. Using approved therapies for one condition to treat another, or drug repurposing, offers new avenues to speed Parkinsons therapeutic development, said Dr Brian Fiske, senior vice president of research programs at the Michael J Fox Foundation, set up by the actor who suffers from the disease, which funded the study. The results from the exenatide studies justify continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinsons. More than 10 million people are currently living with Parkinsons disease, making it the second most common neurodegenerative condition in the world.
IFL Science, 7 August 2017 ; http://www.iflscience.com